Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00003140 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Letrozole After Tamoxifen in Treating Women With Breast Cancer

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 359 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv359
  2. Primary completion date: Oct 2003 to Aug 22, 2003
    • Start date: Aug 1998 to Aug 24, 1998
    v358
  3. Study completion date: Dec 2010 to Oct 2003v357
  4. Primary completion date: Jan 2010 to Oct 2003v356
  5. Re-verified, no change to tracked fieldsv355
Show 45 earlier versionsHide 45 earlier versions
  1. Trial status: Active, Not Recruiting to Completed
    • Study sites: 542 to 57
    • Study completion date: Dec 2010
    v354
  2. Primary completion date changed from estimate of Sep 2002 to Jan 2010v353
  3. 2 versions Re-verified since May 4, 2010, no change to tracked fieldsv351-v352
  4. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 4700 to confirmed 5187
    • Study sites revised (542)
    v350
  5. Site details revised at 4 of 542 sitesv349
  6. Site contacts updated at 1 of 542 sites
    • Publications: 31 to 32
    v348
  7. Study sites revised (542)v347
  8. Study sites revised (542)v346
  9. Study sites revised (542)v345
  10. Lead sponsor: Canadian Cancer Trials Group to NCIC Clinical Trials Groupv344
  11. Site contacts updated at 1 of 542 sitesv343
  12. Study sites: 543 to 542v342
  13. Study sites: 551 to 543v341
  14. Study sites: 552 to 551v340
  15. Study sites: 556 to 552v339
  16. Study sites: 557 to 556v338
  17. Study sites: 558 to 557v337
  18. Study sites: 560 to 558v336
  19. Study sites: 562 to 560v335
  20. Study sites: 561 to 562v334
  21. Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 550 to 561
    v333
  22. Trial status: Recruiting to Active, Not Recruiting
    • Study sites revised (550)
    v332
  23. Study sites revised (550)v331
  24. Study sites: 548 to 550v330
  25. Study sites: 549 to 548v329
  26. Study sites: 550 to 549v328
  27. Study sites: 548 to 550v327
  28. Study sites: 546 to 548v326
  29. Study sites: 547 to 546v325
  30. Study sites: 548 to 547v324
  31. Study sites: 547 to 548v323
  32. Study sites revised (547)v322
  33. Study sites: 545 to 547v321
  34. Study sites: 548 to 545v320
  35. Study sites: 534 to 548v319
  36. Study sites: 528 to 534v318
  37. Study sites: 526 to 528v317
  38. Study sites: 528 to 526v316
  39. Study sites: 530 to 528v315
  40. Study sites: 529 to 530v314
  41. Study sites: 545 to 529v313
  42. Study sites: 546 to 545v312
  43. Study sites revised (546)v311
  44. Study sites: 544 to 546v310
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years.
Trial Details
NCT Number NCT00003140
Lead Sponsor NCIC Clinical Trials Group
Collaborators: National Cancer Institute (NCI), North Central Cancer Treatment Group, ETOP IBCSG Partners Foundation, Eastern Cooperative Oncology Group, SWOG Cancer Research Network, Cancer and Leukemia Group B, European Organisation for Research and Treatment of Cancer - EORTC
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 5,187 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov